Companies with positive PBAC recommendations from November are already dealing with the indirect consequences of next April and it is just one of the challenges facing pharmaceutical, medical device and diagnostic companies as we look forward to 2023.
Next year will be even tougher unless the downward trajectory can be halted
December 8, 2022 Latest NewsBioPharmaComment
Latest Video
New Stories
-
And this is why it's very hard not to be cynical in this system because this committee gets to set its own rules
November 11, 2026 - - Latest News -
The negotiating room is getting smaller as officials narrow the scope
November 11, 2026 - - Latest News -
PBAC sets out its expectations for AI in medicines submissions
November 11, 2026 - -
And this is why it's very hard not to be cynical in this system becasue this committee gets to set its own rules
November 11, 2026 - - Latest News -
Dispatch AI Index finds routine AI use but questions over governance
November 10, 2026 - - News of the Day -
Mayne Pharma sells Salisbury business to Evaris Pharma for $55.5 million
November 10, 2026 - - Latest News -
Bristol Myers Squibb Australia riders more than double their target for Rare Cancers Australia
November 10, 2026 - - Latest News

